GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Additional Paid-In Capital

SELLAS Life Sciences Group (FRA:RXK3) Additional Paid-In Capital : €217.57 Mil(As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Additional Paid-In Capital?


SELLAS Life Sciences Group's quarterly additional paid-in capital declined from Sep. 2023 (€192.35 Mil) to Dec. 2023 (€191.90 Mil) but then increased from Dec. 2023 (€191.90 Mil) to Mar. 2024 (€217.57 Mil).

SELLAS Life Sciences Group's annual additional paid-in capital increased from Dec. 2021 (€140.67 Mil) to Dec. 2022 (€174.41 Mil) and increased from Dec. 2022 (€174.41 Mil) to Dec. 2023 (€191.90 Mil).


SELLAS Life Sciences Group Additional Paid-In Capital Historical Data

The historical data trend for SELLAS Life Sciences Group's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Additional Paid-In Capital Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.52 119.90 140.67 174.41 191.90

SELLAS Life Sciences Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 190.69 188.92 192.35 191.90 217.57

SELLAS Life Sciences Group Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

SELLAS Life Sciences Group Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group (FRA:RXK3) Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group (FRA:RXK3) Headlines

No Headlines